{"id":444,"date":"2013-01-18T19:42:02","date_gmt":"2013-01-18T19:42:02","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=444"},"modified":"2026-02-25T20:20:44","modified_gmt":"2026-02-25T20:20:44","slug":"high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2013\/01\/18\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\/","title":{"rendered":"High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome (Contributed by Dr. Virginie Bubien)"},"content":{"rendered":"<p><i>PTEN<\/i> hamartoma tumor syndrome (PHTS) encompasses several clinical syndromes with germline mutations in the <i>PTEN<\/i> tumor suppressor gene, including Cowden syndrome, characterized by an increased risk of breast and thyroid cancers. Because PHTS is rare, data regarding cancer risks are limited.<\/p>\n<p>We recruited a significant number of PHTS patients with germline <i>PTEN<\/i> mutations from the Institut Bergoni\u00e9 genetic lab in order to better estimate cancer risks. This study showed a considerably high cumulative risk of different cancers for patients with PHTS, especially for women, and enables us to clarify and adapt recommendations for management of these patients. (<a href=\"http:\/\/jmg.bmj.com\/content\/early\/2013\/01\/17\/jmedgenet-2012-101339\">http:\/\/jmg.bmj.com\/content\/early\/2013\/01\/17\/jmedgenet-2012-101339<\/a> )<!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PTEN hamartoma tumor syndrome (PHTS) encompasses several clinical syndromes with germline mutations in the PTEN tumor suppressor gene, including Cowden syndrome, characterized by an increased risk of breast and thyroid cancers. Because PHTS is rare, data regarding cancer risks are limited. We recruited a significant number of PHTS patients with germline PTEN mutations from the [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/jmg\/2013\/01\/18\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-444","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome (Contributed by Dr. Virginie Bubien) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2013\/01\/18\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome (Contributed by Dr. Virginie Bubien) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"PTEN hamartoma tumor syndrome (PHTS) encompasses several clinical syndromes with germline mutations in the PTEN tumor suppressor gene, including Cowden syndrome, characterized by an increased risk of breast and thyroid cancers. Because PHTS is rare, data regarding cancer risks are limited. We recruited a significant number of PHTS patients with germline PTEN mutations from the [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2013\/01\/18\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2013-01-18T19:42:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-25T20:20:44+00:00\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/01\\\/18\\\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/01\\\/18\\\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome (Contributed by Dr. Virginie Bubien)\",\"datePublished\":\"2013-01-18T19:42:02+00:00\",\"dateModified\":\"2026-02-25T20:20:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/01\\\/18\\\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\\\/\"},\"wordCount\":122,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/01\\\/18\\\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/01\\\/18\\\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/01\\\/18\\\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\\\/\",\"name\":\"High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome (Contributed by Dr. Virginie Bubien) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"datePublished\":\"2013-01-18T19:42:02+00:00\",\"dateModified\":\"2026-02-25T20:20:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/01\\\/18\\\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/01\\\/18\\\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/01\\\/18\\\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome (Contributed by Dr. Virginie Bubien)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome (Contributed by Dr. Virginie Bubien) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2013\/01\/18\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\/","og_locale":"en_US","og_type":"article","og_title":"High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome (Contributed by Dr. Virginie Bubien) - JMG Contact blog","og_description":"PTEN hamartoma tumor syndrome (PHTS) encompasses several clinical syndromes with germline mutations in the PTEN tumor suppressor gene, including Cowden syndrome, characterized by an increased risk of breast and thyroid cancers. Because PHTS is rare, data regarding cancer risks are limited. We recruited a significant number of PHTS patients with germline PTEN mutations from the [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2013\/01\/18\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\/","og_site_name":"JMG Contact blog","article_published_time":"2013-01-18T19:42:02+00:00","article_modified_time":"2026-02-25T20:20:44+00:00","author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2013\/01\/18\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2013\/01\/18\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome (Contributed by Dr. Virginie Bubien)","datePublished":"2013-01-18T19:42:02+00:00","dateModified":"2026-02-25T20:20:44+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2013\/01\/18\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\/"},"wordCount":122,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2013\/01\/18\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2013\/01\/18\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\/","url":"https:\/\/blogs.bmj.com\/jmg\/2013\/01\/18\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\/","name":"High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome (Contributed by Dr. Virginie Bubien) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"datePublished":"2013-01-18T19:42:02+00:00","dateModified":"2026-02-25T20:20:44+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2013\/01\/18\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2013\/01\/18\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2013\/01\/18\/high-cumulative-risks-of-cancer-in-patients-with-pten-hamartoma-tumour-syndrome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome (Contributed by Dr. Virginie Bubien)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=444"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/444\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}